Invokana Lawsuit Gains Support From European Medicines Agency Warnings

February 09, 2016 – – Tracey & Fox reports on warnings from the European Medicines Agency (EMA) which have linked Invokana and other SLGT2 inhibitor diabetes drugs to more than 100 cases of diabetic ketoacidosis from across the world. The EMA’s warning noted, “Although diabetic ketoacidosis is usually accompanied by high blood sugar levels, in a number of these reports, blood sugar levels were only moderately increased. These uncharacteristic blood levels could delay diagnosis and treatment.”

Diabetic ketoacidosis is a serious medical condition which can lead to a comatose state or even death. It is created when the body does not get enough of the glucose (or sugar) that it requires for energy. To get more energy, a body in this condition begins to burn fat, producing ketones, which can be harmful. Allegations have been made which link the drug to several conditions, including ketoacidosis, heart attack, kidney failure, stroke, and bone fractures.

SGLT2 inhibitor medications help the body to remove excess glucose via the kidneys and urine. They control blood sugar levels for type-2 diabetes patients in this way. The U.S. Food and Drug Administration issued a warning regarding these drugs, after receiving multiple reports of patients who took the drug and later developed ketoacidosis. FDA reports show that all patients in these instances required hospitalization. Several patients also reported requiring dialysis due to complete kidney failure.

The attorneys at Tracey & Fox are currently working to help assist anyone who may have used Invokana or another SLGT2 inhibitor drug and who subsequently suffered from health complications. These individuals deserve the opportunity to explore all of their legal options, and make informed decisions moving forward. In order to help those deserving pursue justice, Tracey & Fox offers free legal consultations for those involved, and sponsors resource website TheProductLawyers.com, designed to keep people up to date on the latest Invokana news.

To request additional information regarding Invokana or other SLGT2 inhibitor drugs, or to ask questions, please contact the attorneys at Tracey & Fox by calling 877-671-6480.

###

Contact Tracey & Fox:

Sean Tracey
877-671-6480
440 Louisiana Street , Suite 1901
Houston, TX 77002

ReleaseID: 60008027